Rationale,Design,and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 × 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowering in Patients with Acute Ischaemic Stroke Eligible for Thrombolysis Treatment

Abstract

Rationale

Controversy exists over the optimal dose of intravenous (iv) recombinant tissue plasminogen activator (rt-PA) and degree of blood pressure (BP) control in acute ischaemic stroke (AIS). Asian studies suggest low-dose (0·6 mg/kg) is more efficacious than standard-dose (0·9 mg/kg) iv rt-PA, and guidelines recommend reducing systolic BP to <185 mmHg before and <180 mmHg after use of iv rt-PA, despite observational studies indicating better outcomes at much lower (<140 mmHg) systolic BP levels in this patient group.

Aims

The study aims to assess in thrombolysis-eligible AIS patients whether: (i) low-dose (0·6 mg/kg body weight; maximum 60 mg) iv rt-PA has non-inferior efficacy and lower risk of symptomatic intracerebral haemorrhage (sICH) compared to standard-dose (0·9 mg/kg body weight; maximum 90 mg) iv rt-PA; and (ii) early intensive BP lowering (systolic target 130–140 mmHg) has superior efficacy and lower risk of any ICH compared to guideline-recommended BP control (systolic target < 180 mmHg).

Design

The ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED) trial is an independent, 2 × 2 quasi-factorial, active-comparison, prospective, randomized, open blinded endpoint (PROBE), clinical trial that is evaluating Arm [A] ‘rt-PA dose’ and/or Arm [B] ‘BP control’, using central Internet randomization and data collection in patients fulfilling local criteria for thrombolysis and clinician uncertainty over the study treatments. The treatment arms will be analyzed separately.

Study outcomes

The primary study outcome in both trial Arms is death or disability according to the modified Rankin scale (mRS, scores 2–6) assessed at 90 days. Secondary outcomes include sICH, any ICH, a shift (‘improvement’) in function across mRS scores, separately on death and disability, early neurological deterioration, recurrent major vascular events, health-related quality of life, length of hospital stay, need for permanent residential care, and health care costs.

Results

Following launch of the trial in February 2012, the study has recruited more than 2500 patients across a global network of approximately 100 sites in 15 countries. The required sample sizes are 3300 for Arm [A] and 2300 for Arm [B], which will provide >90% power to detect non-inferiority of low-dose iv rt-PA and superiority of intensive BP lowering on the primary clinical outcome, respectively.

Conclusions

Low-dose iv rt-PA and early intensive BP lowering could provide more affordable and safer use of thrombolysis treatment for patients with AIS worldwide.

Keywords

acute ischaemic stroke Alteplase dose hypertension rt-PA thrombolysis

Get full access to this article

View all access options for this article.

References

Emberson

Lees

Lyden

. Effect of treatment delay, age and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–35.

Wardlaw

Murray

Berge

. Recombiant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet 2012; 379: 2364–72.

The national institute of disorders and stroke rt-PA stroke study group: Tissue Plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7.

Brott

Haley

Jr Levy

. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632–40.

Haley

Jr Levy

Brott

. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 1992; 23: 641–5.

Haley

Jr Brott

Sheppard

. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke: The TPA Bridging Study Group. Stroke 1993; 24: 1000–4.

Hacke

Donnan

Fieschi

. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768–74.

Hacke

Kaste

Bluhmki

. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317–29.

Jauch

Saver

Adams

. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947.

10.

Saver

. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: Novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61: 1066–70.

11.

Mori

Yoneda

Tabuchi

. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976–82.

12.

Yamaguchi

Kikuchi

Hayakawa

. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute ischaemic stroke; in Yamaguchi

Mori

Minematsu

Zoppo

(eds): Thrombolytic Therapy in Acute Ischaemic Stroke III. Tokyo, Springer-Verlag, 1995: 223–9.

13.

Ueshima

Matsuo

. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002; 87: 544–6.

14.

Iso

Folsom

Koike

. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: Correlates in nonsmoking Japanese and Caucasian men and women. Thromb Haemost 1993; 70: 475–80.

15.

Murata

. Genetic polymorphisms associated with thrombotic disorders in the Japanese population Fibrinolysis Proteolysis 2000; 14: 155–64.

16.

Shaw

Meunier

Lindsell

Pancioli

Holland

. Making the right choice: Optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res 2010; 126: e305–11.

17.

Yamaguchi

Mori

Minematsu

. Alteplase at 0·6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810–5.

18.

Toyoda

Koga

Naganuma

. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: General outcomes and prognostic factors from the SAMURAI register. Stroke 2009; 40: 3591–5.

19.

Nakagawara

Minematsu

Okada

. Thrombolysis with 0·6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984–9.

20.

Pandian

Srikanth

Read

Thrift

. Poverty and stroke in India: A time to act. Stroke 2007; 38: 3063–9.

21.

Sharma

Venketasubramanian

. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke 2011; 6: 523–30.

22.

Wardlaw

Koumellis

Liu

. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev 2013; (5): Art. No.: CD000514. doi: 10.1002/14651858.CD000514.pub3.

23.

Qureshi

Ezzeddine

Nasar

. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med 2007; 25: 32–8.

24.

Geeganage

Bath

. Relationship between therapeutic changes in blood pressure and outcomes in acute stroke: A metaregression. Hypertension 2009; 54: 775–81.

25.

Qureshi

. Acute hypertensive response in patients with stroke: Pathophysiology and management. Circulation 2008; 118: 176–87.

26.

Tikhonoff

Zhang

Richart

Staessen

. Blood pressure as a prognostic factor after acute stroke. Lancet Neurol 2009; 8: 938–48.

27.

Elewa

Kozak

Johnson

Ergul

Fagan

. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens 2007; 25: 855–9.

28.

Brott

Kothari

. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 1998; 29: 1504–9.

29.

Tsivgoulis

Frey

Flaster

. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke 2009; 40: 3631–4.

30.

Wahlgren

Ahmed

Eriksson

. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST). Stroke 2008; 39: 3316–22.

31.

Ahmed

Wahlgren

Brainin

. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: Retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40: 2442–9.

32.

Sandset

Bath

Boysen

. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): A randomised, placebo-controlled, double-blind trial. Lancet 2011; 377: 741–50.

33.

The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): A partial-factorial randomised controlled trial. Lancet 2015; 385: 617–28.

34.

Anderson

Heeley

Huang

. Rapid blood pressure lowering in acute intracerebral hemorrhage. New Engl J Med 2013; 368: 2355–65.

35.

Bamford

Sandercock

Warlow

Slattery

. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989; 20: 828.

36.

Brott

Adams

Jr Olinger

. Measurements of acute cerebral infarction: A clinical examination scale. Stroke 1989; 20: 864–70.

37.

Bath

PMW

Lees

Schellinger

. On behalf of the European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012; 43: 1171–8.

38.

Howard

Waller

Voeks

. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke 2012; 43: 664–9.

39.

Rabin

de Charro

. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001; 33: 337–43.

40.

Wardlaw

Murray

Berge

del Zoppo

. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014; (7): Art. No.: CD000213. doi: 10.1002/14651858.CD000213.pub3.

41.

Georgladis

Memon

Shah

. Comparison of partial (·6 mg/kg) versus full-dose (·9 mg/kg) intravenous recombinant tissue plasminogen activator followed by endovascular treatment for acute ischemic stroke: A meta-analysis. J Neuroimaging 2011; 21: 113–20.

42.

Menon

Saver

Prabhakaran

. Rick score for intracranial haemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012; 43: 2293–9.